Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Assets (2016 - 2025)

Historic Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $258.3 million.

  • Akebia Therapeutics' Current Assets rose 15802.64% to $258.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.3 million, marking a year-over-year increase of 15802.64%. This contributed to the annual value of $113.8 million for FY2024, which is 365.47% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Current Assets of $258.3 million as of Q3 2025, which was up 15802.64% from $234.7 million recorded in Q2 2025.
  • Akebia Therapeutics' Current Assets' 5-year high stood at $365.0 million during Q1 2021, with a 5-year trough of $100.1 million in Q3 2024.
  • Moreover, its 5-year median value for Current Assets was $203.8 million (2025), whereas its average is $207.4 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Current Assets crashed by 6157.44% in 2023, and later soared by 15802.64% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Current Assets stood at $271.1 million in 2021, then tumbled by 31.7% to $185.2 million in 2022, then tumbled by 36.2% to $118.1 million in 2023, then fell by 3.65% to $113.8 million in 2024, then surged by 126.95% to $258.3 million in 2025.
  • Its Current Assets stands at $258.3 million for Q3 2025, versus $234.7 million for Q2 2025 and $203.8 million for Q1 2025.